Discontinued drugs in 2006: Pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1327-1344

  Ozdemir, Cevdet ^a   Akdis, Cezmi A ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Arthritis; Asthma; Atopic eczema; Discontinued drugs; New drugs; Psoriasis

Indexed keywords

AD 452; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; ASF 1020; AZD 9343; BALICATIB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CS 526; DERMATOLOGICAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DW 908E; GASTROINTESTINAL AGENT; HL 10; IMMUNOGLOBULIN E ANTIBODY; LUNG SURFACTANT; MONTELUKAST; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PLACEBO; PROSTAGLANDIN INHIBITOR; QAK 423; RESPIRATORY TRACT AGENT; S 5751; SPASMOLYTIC AGENT; TALIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALATEGRAST; ANTIALLERGIC AGENT; NEW DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; NONHUMAN; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG APPROVAL; DRUG INDUSTRY; METHODOLOGY; REVIEW; STANDARD;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIRHEUMATIC AGENTS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; RESPIRATORY SYSTEM AGENTS;

EID: 34548547155     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1327     Document Type: Article

References (23)

1. AKDIS M, AKDIS CA: Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol, (2007) 119(4):780-791.
2. SHERIDAN C: TeGenero, fiasco prompts regulatory rethink. Nat. Biotechnol. (2006) 24(5):475-476.
3. 7 integrin antagonist. Am. J. Resp. Crit. Care. Med. (2003) 167(7):A640.
4. 1 integrin antagonist after oral administration at single and multiple once daily ascending doses in healthy volunteers. J. Clin. Pharmacol. (2004) 44:1368-1378.
5. 7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur. J. Clin. Pharmacol, (2006) 62:83-85.
6. SINGH J, ADAMS S, CARTER MB et al.: Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr. Top. Med. Chem. (2004) 4(14):1497-1507.
7. ROLIN S, MASEREEL B, DOGNÉ JM: Prostanoids as pharmacological targets in COPD and asthma. Eur. J. Pharmacol. (2006) 533(1-3):89-100.
8. KESECIOGLU J, HAITSMA JJ: Surfactant therapy in adults with acute lung injury/acute respiratory distress syndrome. Curr. Opin. Crit. Care (2006) 12(1):55-60.
9. LEUNG DY, SAMPSON HA, YUNGINGER JW et al.: Avon Longitudinal Study of Parents and Children Study Team Effect of anti-IgE therapy in patients with peanut allergy. N. Engl, J. Med (2003) 348(11):986-993.
10. MATTHEWS JB, RAMOS E, BLUESTONE JA.- Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. (2003) 3:794-803.
11. BOON L, LAMAN JD, ORTIZ-BUIJSSE A et al.: Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology (2002) 174:53-65.
12. TRAVIS S, YAP LM, HAWKEY C et al.: RDP Investigators Study Group. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. (2005) 11(8):713-719.
13. TREMAINE WJ, BRZEZINSKI A, KATZ JA et al.: AXYS ULCERATIVE COLITIS STUDY GROUP: Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment. Pharmacol, Ther (2002) 16:407-413.
14. RICE KD, WANG VR, GANG LOFF AR et al.: Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. (2000) 16; 10(20):2361-2366.
15. HESSE C, LUNTZ SP. SIEDLER H, et al.: Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. Br. J. Clin. Pharmacol. (2006) 61(4):414-419.
16. VAKIL N: Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2004) 15;19(10):1041-1049.
17. ITO K, KINOSHITA K, TOMIZAWA A et al.: The anti-secretory and anti-ulcer properties of R-105266, a novel acid pump antagonist. Gut (2001) 49(Suppl. 3) (Abstract 3061).
18. MIWATASHI S, ARIKAEA Y, KOTANI E et al.: Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N -[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J. Med. Chem. (2005) 22;48(19):5966-5979.
19. FALGUEYRET JP, DESMARAIS S, OBALLA R et al.: Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-targer cathepsins and reduced functional selectivity. J. Med. Chem. (2005) 48(24):7535-7543.
20. SCHREPFER S, DEUSE T, KOCH-NOLTE F, DETTER C, REICHENSPURNER H: FK778: new cellular and molecular mechanisms of action. Transplant. Proc. (2006) 38(3):757-761.
21. KAPLAN MJ: FK-778 Astellas. Curn Opin. Investig, Drugs (2005) 6(5):526-536.
22. LINK JO, ZIPFEL S: Advances in cathepsin S inhibitor design. Curr. Opin. Drug. Discov. Dev. (2006) 9(4):471-482.
23. VASILJEVA O, REINHECKEL T, PETERS C, TURK D, TURK V, TURK B: Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. (2007) 13(3):385-401.